Cartesian Therapeutics is working on CAR-T for autoimmune conditions, but with the unique angle that it is using a mRNA approach rather than DNA
- 1 hour ago
- 1 min read
Chairman & CEO Carsten Brunn describes the potential advantages of this, which includes that no lymphodepletion is needed. The company is currently in a pivotal study for myasthenia gravis.









.png)
